Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Cancer survival worse in RA patients

Written by | 19 Aug 2016

Survival was more than 2 years shorter in breast, prostate cancers.  Patients with rheumatoid arthritis (RA) had a 40% to 50% increased mortality risk if they developed breast… read more.

Less painkilling medication with breast-cancer surgery after opiate-free anesthesia

Written by | 12 Aug 2016

New research presented at Euroanaesthesia 2016 (London 27-30 May) shows that patients undergoing breast cancer surgery need less painkilling medication post-surgery if they have anaesthesia that is free… read more.

Rise in post-surgical opioid prescriping raises concerns, elicits new US guideline

Written by | 5 Aug 2016

by Bruce Sylvester: Patients who have undergone common surgeries are receiving opioid painkillers at an increasing rate, researchers reported on March 18, 2016 in JAMA/Journal of the American… read more.

EHA 2016: Consolidation and maintenance therapy for multiple myeloma: is it the new standard? Professor Paul Richardson (Harvard Medical School, Boston, USA) and Professor Maria-Victoria Mateos (Salamanca, Spain) discuss the meta-analysis of OS in myeloma with maintenance therapy presented at ASCO and EHA this year, along with strategies for continuous therapies

Written by | 3 Aug 2016

Consolidation and maintenance therapy for multiple myeloma: is it the new standard?   Professor Antonio Palumbo (University of Turin, Italy) and Professor Paul Richardson (Harvard Medical School, Boston,… read more.

EHA 2016: Pathophysiology and diagnosis of multiple myeloma bone disease. The chair of this year’s EHA educational session on myeloma, Professor Roman Hajek (University of Ostrava, Czech Republic), discusses highlights from the session.

Written by | 2 Aug 2016

Pathophysiology and diagnosis of multiple myeloma bone disease Evangelos Terpos, University of Athens School of Medicine, Greece Osteolytic bone disease is the most common complication of MM and… read more.

EHA 2016: Pathophysiology and diagnosis of multiple myeloma bone disease. The chair of this year's EHA educational session on myeloma, Professor Roman Hajek (University of Ostrava, Czech Republic), discusses highlights from the session.

Written by | 2 Aug 2016

Pathophysiology and diagnosis of multiple myeloma bone disease Evangelos Terpos, University of Athens School of Medicine, Greece Osteolytic bone disease is the most common complication of MM and… read more.

EHA 2016: Preventing clonal evolution in multiple myeloma – evidence from clinical trials. Professor Roman Hájek from the Czech Republic discussed the clinical implications of clonal evolution in multiple myeloma (MM) and summarised the latest clinical data.

Written by | 19 Jul 2016

Preventing clonal evolution in multiple myeloma – evidence from clinical trials by Maria Dalby Professor Roman Hájek from the Czech Republic discussed the clinical implications of clonal evolution… read more.

Pioglitazone shows efficacy against a chronic liver disease

Written by | 11 Jul 2016

by Bruce Sylvester: Pioglitazone shows efficacy against the progression of nonalcoholic steatohepatitis, or NASH, a chronic liver disease caused by a buildup of fat. Researchers reported this finding… read more.

ASCO 2016: Elderly glioblastoma patients achieve longer survival with radiation plus temozolomide

Written by | 5 Jul 2016

by Bruce Sylvester: Researchers from a randomized phase III trial report that addition of temozolomide (Temodar) chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide,… read more.

ASCO 2016: Previously untreatable advanced bladder cancer patients respond to immunotherapy

Written by | 4 Jul 2016

by Bruce Sylvester: Anti-PD-L1 immunotherapy atezolizumab (TECENTRIQ) has shown efficacy in previously untreated patients with advanced bladder cancer who are ineligible for standard treatment with cisplatin.

ASCO 2016: Targeted therapy shows efficacy in advanced small cell lung cancer

Written by | 1 Jul 2016

by Bruce Sylvester: Investigative rovalpituzumab tesirine (Rova-T) appears to be safe and shows efficacy in treating advanced small cell lung cancer (SCLC), researchers reported in June, 2016 at… read more.

ASCO 2016: Melanoma 3-year survival is robust after pembrolizumab treatment

Written by | 30 Jun 2016

by Bruce Sylvester: A follow-up evaluation of subjects from the phase 1b trial (KEYNOTE-001) of newly diagnosed and previously treated patients with advanced melanoma revealed a 40% survival… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.